Dyax Corp. and Genzyme Enter Into License Agreement for Discovery of Therapeutic Antibodies

03-Jun-2004

Cambridge, Mass. - Dyax Corp announced that it has granted a non-exclusive license to its proprietary antibody phage display libraries to Genzyme Corporation for the discovery of human antibodies, initially for use in the research field and with options for therapeutic antibody product development.

Under the terms of the agreement, Dyax will receive payment that includes an upfront technology license fee, clinical milestone payments, and royalties on net sales of products that may result from Genzyme's use of the Dyax libraries.

Genzyme also has the option to have Dyax perform funded research on its behalf. The agreement provides Genzyme with a license to Dyax's antibody phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous